Factor XIII – an under diagnosed deficiency – are we using the right assays?
Background: The clot solubility test is the most widely used method for detection of factor (F)XIII deficiency. However, it will only detect severe deficiencies; consequently mild deficiencies and heterozygous states are probably under diagnosed. Objective: As an alternative first‐line screening te...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and haemostasis 2010-11, Vol.8 (11), p.2478-2482 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2482 |
|---|---|
| container_issue | 11 |
| container_start_page | 2478 |
| container_title | Journal of thrombosis and haemostasis |
| container_volume | 8 |
| creator | LAWRIE, A. S. GREEN, L. MACKIE, I. J. LIESNER, R. MACHIN, S. J. PEYVANDI, F. |
| description | Background: The clot solubility test is the most widely used method for detection of factor (F)XIII deficiency. However, it will only detect severe deficiencies; consequently mild deficiencies and heterozygous states are probably under diagnosed. Objective: As an alternative first‐line screening test, we assessed an automated quantitative ammonia release assay (QARA). Patients/methods: Inter‐assay imprecision was evaluated with commercial normal and pathological control plasmas (10 replicates on each of 5 days). Using the QARA and other commercial assays a comparative assessment of congenital (FXIII range |
| doi_str_mv | 10.1111/j.1538-7836.2010.04028.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_846903335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>846903335</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4188-bf3d943cc56ff925d296b6a904af04e830646d1f35b4bf3221629e107048455c3</originalsourceid><addsrcrecordid>eNqNkL1OwzAQgC0EoqXwCsgbU4L_ktgDQghRGlQJhiKxWY7jtKnSpNiN2my8A2_Ik5CQtjO33OnuuzvpAwBi5OM2bpc-Dij3Ik5Dn6C2ixgi3N-dgOFxcHqoBaUDcOHcEiEsAoLOwYCgiEQowkPwNlZ6U1n4Eccx_Pn6hqqEdZkaC9NczcvKmRSmJst1bkrd9IQ1cGtg7fJyDjcLA20-X2ygck417v4SnGWqcOZqn0fgffw0e5x409fn-PFh6mmGOfeSjKaCUa2DMMsECVIiwiRUAjGVIWY4RSELU5zRIGEtSwgOiTAYRYhxFgSajsBNf3dtq8_auI1c5U6bolClqWonOQsFopQGLcl7UtvKOWsyubb5StlGYiQ7nXIpO1OysyY7nfJPp9y1q9f7J3WyMulx8eCvBe56YJsXpvn3Yfkym3QV_QWpW4L4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>846903335</pqid></control><display><type>article</type><title>Factor XIII – an under diagnosed deficiency – are we using the right assays?</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>LAWRIE, A. S. ; GREEN, L. ; MACKIE, I. J. ; LIESNER, R. ; MACHIN, S. J. ; PEYVANDI, F.</creator><creatorcontrib>LAWRIE, A. S. ; GREEN, L. ; MACKIE, I. J. ; LIESNER, R. ; MACHIN, S. J. ; PEYVANDI, F.</creatorcontrib><description><![CDATA[Background: The clot solubility test is the most widely used method for detection of factor (F)XIII deficiency. However, it will only detect severe deficiencies; consequently mild deficiencies and heterozygous states are probably under diagnosed. Objective: As an alternative first‐line screening test, we assessed an automated quantitative ammonia release assay (QARA). Patients/methods: Inter‐assay imprecision was evaluated with commercial normal and pathological control plasmas (10 replicates on each of 5 days). Using the QARA and other commercial assays a comparative assessment of congenital (FXIII range < 1–70 u dL−1, n = 9) and acquired (n = 43) deficiencies was made. We also investigated the prevalence of acquired deficiencies in hospitalized patients using residual samples from adult patients (n = 1004) and from a paediatric intensive care unit (ICU, n = 56). Results: Assay imprecision was acceptably low (normal control: mean 86.6 u dL−1; cv = 2.0%; pathological control: mean 27.5 u dL−1; cv = 3.8%). Using an iodoacetamide blanking procedure, the QARA results (FXIII range < 1–70 u dL−1) exhibited close agreement with those from an immuno‐turbidometric FXIII A‐subunit (FXIII‐A) method. There was also good correlation (R2 ≥ 0.89) between the QARA (range 20–180 u dL−1), a second chromogenic assay, the FXIII‐A and FXIII A+B‐subunit ELISA. We found that 21% of samples from adult patients had FXIII levels < 70 u dL−1 (mean normal ± 2 SD 73–161 u dL−1) with 6% < 50 u dL−1. Within the paediatric ICU samples, 52% were < 70 u dL−1, with 21% < 50 u dL−1. Conclusions: Our data demonstrates that the automated assay is sensitive, highly reproducible and the results from clinical samples suggest that acquired FXIII deficiency is a relatively common phenomenon in hospital patients after surgery and in ICU.]]></description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/j.1538-7836.2010.04028.x</identifier><identifier>PMID: 20727071</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>acquired FXIII deficiency ; Adult ; Automation ; Chemistry, Clinical - methods ; Child ; Cohort Studies ; factor XIII ; Factor XIII - analysis ; factor XIII deficiency ; Factor XIII Deficiency - blood ; Factor XIII Deficiency - diagnosis ; FXIII assay ; Heterozygote ; Humans ; Immune System ; Intensive Care Units ; Nephelometry and Turbidimetry - methods ; Prevalence ; Reproducibility of Results ; Wound Healing</subject><ispartof>Journal of thrombosis and haemostasis, 2010-11, Vol.8 (11), p.2478-2482</ispartof><rights>2010 International Society on Thrombosis and Haemostasis</rights><rights>2010 International Society on Thrombosis and Haemostasis.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4188-bf3d943cc56ff925d296b6a904af04e830646d1f35b4bf3221629e107048455c3</citedby><cites>FETCH-LOGICAL-c4188-bf3d943cc56ff925d296b6a904af04e830646d1f35b4bf3221629e107048455c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20727071$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LAWRIE, A. S.</creatorcontrib><creatorcontrib>GREEN, L.</creatorcontrib><creatorcontrib>MACKIE, I. J.</creatorcontrib><creatorcontrib>LIESNER, R.</creatorcontrib><creatorcontrib>MACHIN, S. J.</creatorcontrib><creatorcontrib>PEYVANDI, F.</creatorcontrib><title>Factor XIII – an under diagnosed deficiency – are we using the right assays?</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description><![CDATA[Background: The clot solubility test is the most widely used method for detection of factor (F)XIII deficiency. However, it will only detect severe deficiencies; consequently mild deficiencies and heterozygous states are probably under diagnosed. Objective: As an alternative first‐line screening test, we assessed an automated quantitative ammonia release assay (QARA). Patients/methods: Inter‐assay imprecision was evaluated with commercial normal and pathological control plasmas (10 replicates on each of 5 days). Using the QARA and other commercial assays a comparative assessment of congenital (FXIII range < 1–70 u dL−1, n = 9) and acquired (n = 43) deficiencies was made. We also investigated the prevalence of acquired deficiencies in hospitalized patients using residual samples from adult patients (n = 1004) and from a paediatric intensive care unit (ICU, n = 56). Results: Assay imprecision was acceptably low (normal control: mean 86.6 u dL−1; cv = 2.0%; pathological control: mean 27.5 u dL−1; cv = 3.8%). Using an iodoacetamide blanking procedure, the QARA results (FXIII range < 1–70 u dL−1) exhibited close agreement with those from an immuno‐turbidometric FXIII A‐subunit (FXIII‐A) method. There was also good correlation (R2 ≥ 0.89) between the QARA (range 20–180 u dL−1), a second chromogenic assay, the FXIII‐A and FXIII A+B‐subunit ELISA. We found that 21% of samples from adult patients had FXIII levels < 70 u dL−1 (mean normal ± 2 SD 73–161 u dL−1) with 6% < 50 u dL−1. Within the paediatric ICU samples, 52% were < 70 u dL−1, with 21% < 50 u dL−1. Conclusions: Our data demonstrates that the automated assay is sensitive, highly reproducible and the results from clinical samples suggest that acquired FXIII deficiency is a relatively common phenomenon in hospital patients after surgery and in ICU.]]></description><subject>acquired FXIII deficiency</subject><subject>Adult</subject><subject>Automation</subject><subject>Chemistry, Clinical - methods</subject><subject>Child</subject><subject>Cohort Studies</subject><subject>factor XIII</subject><subject>Factor XIII - analysis</subject><subject>factor XIII deficiency</subject><subject>Factor XIII Deficiency - blood</subject><subject>Factor XIII Deficiency - diagnosis</subject><subject>FXIII assay</subject><subject>Heterozygote</subject><subject>Humans</subject><subject>Immune System</subject><subject>Intensive Care Units</subject><subject>Nephelometry and Turbidimetry - methods</subject><subject>Prevalence</subject><subject>Reproducibility of Results</subject><subject>Wound Healing</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkL1OwzAQgC0EoqXwCsgbU4L_ktgDQghRGlQJhiKxWY7jtKnSpNiN2my8A2_Ik5CQtjO33OnuuzvpAwBi5OM2bpc-Dij3Ik5Dn6C2ixgi3N-dgOFxcHqoBaUDcOHcEiEsAoLOwYCgiEQowkPwNlZ6U1n4Eccx_Pn6hqqEdZkaC9NczcvKmRSmJst1bkrd9IQ1cGtg7fJyDjcLA20-X2ygck417v4SnGWqcOZqn0fgffw0e5x409fn-PFh6mmGOfeSjKaCUa2DMMsECVIiwiRUAjGVIWY4RSELU5zRIGEtSwgOiTAYRYhxFgSajsBNf3dtq8_auI1c5U6bolClqWonOQsFopQGLcl7UtvKOWsyubb5StlGYiQ7nXIpO1OysyY7nfJPp9y1q9f7J3WyMulx8eCvBe56YJsXpvn3Yfkym3QV_QWpW4L4</recordid><startdate>201011</startdate><enddate>201011</enddate><creator>LAWRIE, A. S.</creator><creator>GREEN, L.</creator><creator>MACKIE, I. J.</creator><creator>LIESNER, R.</creator><creator>MACHIN, S. J.</creator><creator>PEYVANDI, F.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201011</creationdate><title>Factor XIII – an under diagnosed deficiency – are we using the right assays?</title><author>LAWRIE, A. S. ; GREEN, L. ; MACKIE, I. J. ; LIESNER, R. ; MACHIN, S. J. ; PEYVANDI, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4188-bf3d943cc56ff925d296b6a904af04e830646d1f35b4bf3221629e107048455c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>acquired FXIII deficiency</topic><topic>Adult</topic><topic>Automation</topic><topic>Chemistry, Clinical - methods</topic><topic>Child</topic><topic>Cohort Studies</topic><topic>factor XIII</topic><topic>Factor XIII - analysis</topic><topic>factor XIII deficiency</topic><topic>Factor XIII Deficiency - blood</topic><topic>Factor XIII Deficiency - diagnosis</topic><topic>FXIII assay</topic><topic>Heterozygote</topic><topic>Humans</topic><topic>Immune System</topic><topic>Intensive Care Units</topic><topic>Nephelometry and Turbidimetry - methods</topic><topic>Prevalence</topic><topic>Reproducibility of Results</topic><topic>Wound Healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LAWRIE, A. S.</creatorcontrib><creatorcontrib>GREEN, L.</creatorcontrib><creatorcontrib>MACKIE, I. J.</creatorcontrib><creatorcontrib>LIESNER, R.</creatorcontrib><creatorcontrib>MACHIN, S. J.</creatorcontrib><creatorcontrib>PEYVANDI, F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LAWRIE, A. S.</au><au>GREEN, L.</au><au>MACKIE, I. J.</au><au>LIESNER, R.</au><au>MACHIN, S. J.</au><au>PEYVANDI, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factor XIII – an under diagnosed deficiency – are we using the right assays?</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2010-11</date><risdate>2010</risdate><volume>8</volume><issue>11</issue><spage>2478</spage><epage>2482</epage><pages>2478-2482</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract><![CDATA[Background: The clot solubility test is the most widely used method for detection of factor (F)XIII deficiency. However, it will only detect severe deficiencies; consequently mild deficiencies and heterozygous states are probably under diagnosed. Objective: As an alternative first‐line screening test, we assessed an automated quantitative ammonia release assay (QARA). Patients/methods: Inter‐assay imprecision was evaluated with commercial normal and pathological control plasmas (10 replicates on each of 5 days). Using the QARA and other commercial assays a comparative assessment of congenital (FXIII range < 1–70 u dL−1, n = 9) and acquired (n = 43) deficiencies was made. We also investigated the prevalence of acquired deficiencies in hospitalized patients using residual samples from adult patients (n = 1004) and from a paediatric intensive care unit (ICU, n = 56). Results: Assay imprecision was acceptably low (normal control: mean 86.6 u dL−1; cv = 2.0%; pathological control: mean 27.5 u dL−1; cv = 3.8%). Using an iodoacetamide blanking procedure, the QARA results (FXIII range < 1–70 u dL−1) exhibited close agreement with those from an immuno‐turbidometric FXIII A‐subunit (FXIII‐A) method. There was also good correlation (R2 ≥ 0.89) between the QARA (range 20–180 u dL−1), a second chromogenic assay, the FXIII‐A and FXIII A+B‐subunit ELISA. We found that 21% of samples from adult patients had FXIII levels < 70 u dL−1 (mean normal ± 2 SD 73–161 u dL−1) with 6% < 50 u dL−1. Within the paediatric ICU samples, 52% were < 70 u dL−1, with 21% < 50 u dL−1. Conclusions: Our data demonstrates that the automated assay is sensitive, highly reproducible and the results from clinical samples suggest that acquired FXIII deficiency is a relatively common phenomenon in hospital patients after surgery and in ICU.]]></abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20727071</pmid><doi>10.1111/j.1538-7836.2010.04028.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-7933 |
| ispartof | Journal of thrombosis and haemostasis, 2010-11, Vol.8 (11), p.2478-2482 |
| issn | 1538-7933 1538-7836 1538-7836 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_846903335 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | acquired FXIII deficiency Adult Automation Chemistry, Clinical - methods Child Cohort Studies factor XIII Factor XIII - analysis factor XIII deficiency Factor XIII Deficiency - blood Factor XIII Deficiency - diagnosis FXIII assay Heterozygote Humans Immune System Intensive Care Units Nephelometry and Turbidimetry - methods Prevalence Reproducibility of Results Wound Healing |
| title | Factor XIII – an under diagnosed deficiency – are we using the right assays? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T00%3A28%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factor%20XIII%20%E2%80%93%20an%20under%20diagnosed%20deficiency%20%E2%80%93%20are%20we%20using%20the%20right%20assays?&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=LAWRIE,%20A.%20S.&rft.date=2010-11&rft.volume=8&rft.issue=11&rft.spage=2478&rft.epage=2482&rft.pages=2478-2482&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/j.1538-7836.2010.04028.x&rft_dat=%3Cproquest_cross%3E846903335%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=846903335&rft_id=info:pmid/20727071&rfr_iscdi=true |